AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
GOOGL   1,489.92 (-0.65%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
GE   6.76 (-3.43%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
Log in

NASDAQ:ACERAcer Therapeutics Stock Price, Forecast & News

$3.12
-0.13 (-4.00 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.09
Now: $3.12
$3.31
50-Day Range
$3.07
MA: $3.35
$4.53
52-Week Range
$1.08
Now: $3.12
$7.25
Volume155,000 shs
Average Volume152,091 shs
Market Capitalization$31.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Read More
Acer Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.82 per share

Profitability

Net Income$-29,420,000.00

Miscellaneous

Employees23
Market Cap$31.98 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

How has Acer Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACER stock has decreased by 7.7% and is now trading at $3.12. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Acer Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acer Therapeutics.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Acer Therapeutics.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) released its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.09. View Acer Therapeutics' earnings history.

What price target have analysts set for ACER?

4 brokerages have issued twelve-month price objectives for Acer Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Acer Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 220.5% from the stock's current price. View analysts' price targets for Acer Therapeutics.

Has Acer Therapeutics been receiving favorable news coverage?

News stories about ACER stock have trended negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Acer Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Acer Therapeutics.

Are investors shorting Acer Therapeutics?

Acer Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 578,500 shares, an increase of 8.6% from the June 15th total of 532,700 shares. Based on an average daily trading volume, of 208,000 shares, the short-interest ratio is presently 2.8 days. Approximately 11.3% of the company's stock are sold short. View Acer Therapeutics' Current Options Chain.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
  • Mr. Harry S. Palmin, COO & CFO (Age 49)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
  • Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
  • Ms. Jeannie Kim, VP of Corp. Devel.

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $3.12.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $31.98 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is www.acertx.com.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.